A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients
Clin Pharmacol Ther. 2024 Mar 19. doi: 10.1002/cpt.3255. Online ahead of print.ABSTRACTTamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly variable. The concentration of endoxifen, the 30-100 times more potent metabolite of tamoxifen and bioactivated by the CYP2D6 enzyme, has been described as the most relevant metabolite of tamoxifen metabolism. A genome-wide association study (GWAS) was performed with the objective to identify genetic polymorphisms associated with endoxifen serum concentration levels and clinical outc...
Source: Clinical Breast Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Anabel Beatriz Sanchez-Spitman Stefan B öhringer Vincent Olaf Dezentj é Hans Gelderblom Jesse Joachim Swen Henk-Jan Guchelaar Source Type: research
Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment
CONCLUSIONS: Our findings suggest that the timing of SM diagnosis (synchronous versus metachronous) does not significantly affect survival outcomes following neurosurgical treatment for SM. These results support the consideration of neurosurgical procedures regardless of the temporal pattern of SM manifestation.PMID:38502313 | DOI:10.1007/s00432-024-05657-x (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Mohammed Banat Anna-Laura Potthoff Motaz Hamed Valeri Borger Jasmin E Scorzin Tim Lampmann Harun Asoglu Logman Khalafov Frederic C Schmeel Daniel Paech Alexander Radbruch Louisa Nitsch Johannes Weller Ulrich Herrlinger Marieta Toma Gerrit H Gielen Hartmut Source Type: research
Nipple Reconstruction Using the "Arrow Flap" Technique: Outcomes and Patients Satisfaction
CONCLUSION: The authors believe that the NAC reconstruction has useful functional and aesthetic results particularly appreciated by patients who feel demoralized after breast demolition surgery.PMID:38503614 | DOI:10.1016/j.clbc.2024.01.011 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Vito Cazzato Chiara Stocco Alessandro Scian Luigi Bonat Guarini Giulia Benedetta Sidoti Nadia Renzi Vittorio Ramella Giovanni Papa Source Type: research
Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy
CONCLUSION: This study highlighted the distinct clinical and genetic characteristics of sHR+ BRCA, emphasizing the potential need for optimized treatment strategies.PMID:38503615 | DOI:10.1016/j.clbc.2024.02.016 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Tingting Wang Jinnan Wang Wei Zhao Yueyin Pan Source Type: research
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Int J Clin Oncol. 2024 Mar 18. doi: 10.1007/s10147-023-02465-0. Online ahead of print.ABSTRACTAlthough granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two review...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Tomoya Maeda Yuho Najima Yutaro Kamiyama Shinji Nakao Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Yuji Miumra Makoto Endo Dai Maruyama Tatsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi Baba Nobuaki Source Type: research
A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients
CONCLUSIONS: These findings suggest that BF839 has the potential to effectively mitigate myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patients.PMID:38494684 | DOI:10.6133/apjcn.202403_33(1).0003 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ting Zeng Yu-Hong Deng Chu-Hui Lin Xin-Xin Chen Hai-Xia Jia Xiao-Wu Hu Ting Xia Yun Ling Le-Hong Zhang Teng-Fei Cao Source Type: research
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort
Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print.ABSTRACTTamoxifen is widely used in patients with hormone receptor-positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma concentrations of its most important metabolite, Z-endoxifen. The Z-endoxifen concentration thresholds below which tamoxifen treatment is less efficacious have been proposed but not validated, and prospective trials of individualized tamoxifen treatment to achieve Z-endoxifen concentration thresholds a...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Anna M Mc Laughlin Thomas Helland Fenja Klima Stijn L W Koolen Ron H N van Schaik Ron H J Mathijssen Patrick Neven Jesse J Swen Henk-Jan Guchelaar Florence Dalenc Melanie White-Koning Robin Michelet Gerd Mikus Werner Schroth Thomas M ürdter Hiltrud Brauc Source Type: research
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial
CONCLUSION: The MyHealth study suggested a new strategy for follow-up after early breast cancer as it provided significant improvements in QoL.PMID:38498781 | DOI:10.1200/JCO.23.01447 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Lena Saltb æk Pernille E Bidstrup Randi V Karlsen Beverley L H øeg Trine A Horsboel Federica Belmonte Elisabeth A W Andersen Vibeke Zoffmann Anne S Friberg Mads N Svendsen Helle G Christensen Vesna Glavicic Dorte L Nielsen Susanne O Dalton Christoffer J Source Type: research
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Int J Clin Oncol. 2024 Mar 18. doi: 10.1007/s10147-023-02465-0. Online ahead of print.ABSTRACTAlthough granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two review...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Tomoya Maeda Yuho Najima Yutaro Kamiyama Shinji Nakao Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Yuji Miumra Makoto Endo Dai Maruyama Tatsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi Baba Nobuaki Source Type: research
A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients
CONCLUSIONS: These findings suggest that BF839 has the potential to effectively mitigate myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patients.PMID:38494684 | DOI:10.6133/apjcn.202403_33(1).0003 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ting Zeng Yu-Hong Deng Chu-Hui Lin Xin-Xin Chen Hai-Xia Jia Xiao-Wu Hu Ting Xia Yun Ling Le-Hong Zhang Teng-Fei Cao Source Type: research
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort
Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print.ABSTRACTTamoxifen is widely used in patients with hormone receptor-positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma concentrations of its most important metabolite, Z-endoxifen. The Z-endoxifen concentration thresholds below which tamoxifen treatment is less efficacious have been proposed but not validated, and prospective trials of individualized tamoxifen treatment to achieve Z-endoxifen concentration thresholds a...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Anna M Mc Laughlin Thomas Helland Fenja Klima Stijn L W Koolen Ron H N van Schaik Ron H J Mathijssen Patrick Neven Jesse J Swen Henk-Jan Guchelaar Florence Dalenc Melanie White-Koning Robin Michelet Gerd Mikus Werner Schroth Thomas M ürdter Hiltrud Brauc Source Type: research
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial
CONCLUSION: The MyHealth study suggested a new strategy for follow-up after early breast cancer as it provided significant improvements in QoL.PMID:38498781 | DOI:10.1200/JCO.23.01447 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Lena Saltb æk Pernille E Bidstrup Randi V Karlsen Beverley L H øeg Trine A Horsboel Federica Belmonte Elisabeth A W Andersen Vibeke Zoffmann Anne S Friberg Mads N Svendsen Helle G Christensen Vesna Glavicic Dorte L Nielsen Susanne O Dalton Christoffer J Source Type: research
Breast cancer derived exosomes: Theragnostic perspectives and implications
Clin Chim Acta. 2024 Mar 15:117875. doi: 10.1016/j.cca.2024.117875. Online ahead of print.ABSTRACTBreast cancer (BC) is the most prevalent malignancy affecting women worldwide. Although conventional treatments such as chemotherapy, surgery, hormone therapy, radiation therapy, and biological therapy are commonly used, they often entail significant side effects. Therefore, there is a critical need to investigate more cost-effective and efficient treatment modalities in BC. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, play a crucial role in modulating recipient cell behaviour and driv...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Ram Mohan Ram Kumar Logesh Rajan Suresh Joghee Source Type: research
Paraneoplastic cerebellar and brainstem disorders
Handb Clin Neurol. 2024;200:173-191. doi: 10.1016/B978-0-12-823912-4.00030-X.ABSTRACTParaneoplastic cerebellar and brainstem disorders are a heterogeneous group that requires prompt recognition and treatment to help prevent irreversible neurologic injury. Paraneoplastic cerebellar degeneration is best characterized by Yo antibodies in patients with breast or ovarian cancer. Tr (DNER) antibodies in patients with Hodgkin lymphoma can also present with a pure cerebellar syndrome and is one of the few paraneoplastic syndromes found with hematological malignancy. Opsoclonus-myoclonus-ataxia syndrome presents in both pediatric a...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Justin R Abbatemarco Christian A Vedeler John E Greenlee Source Type: research
Paraneoplastic/autoimmune myelopathies
Handb Clin Neurol. 2024;200:193-201. doi: 10.1016/B978-0-12-823912-4.00017-7.ABSTRACTParaneoplastic myelopathies are a rare but important category of myelopathy. They usually present with an insidious or subacute progressive neurologic syndrome. Risk factors include tobacco use and family history of cancer. Cerebrospinal fluid analysis usually shows lymphocytic pleocytosis with elevated protein. MRI findings suggest that paraneoplastic myelopathies include longitudinally extensive T2 hyperintensities that are tract-specific and accompanied by enhancement, but spinal MRIs can also be normal. The most commonly associated neu...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Mayra Montalvo Eoin P Flanagan Source Type: research
